Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.
A 74-year-old man with idiopathic pulmonary fibrosis (IPF) developed severe dyspnea on exertion after the readministration of imatinib mesylate for chronic myeloid leukemia. Chest X-ray and CT showed ground-glass opacities in both lungs in addition to preexisting honeycombing. Discontinuation of imatinib and methylprednisolone pulse therapy followed by administration of oral prednisolone resulted in improvement in both symptoms and radiographic findings. Imatinib-induced pneumonitis was diagnosed based on the clinical course and findings. Only five previous reports of imatinib-induced pneumonitis have been published in the literature, and this is the first case reported in a patient with IPF.
Yamasawa
Hideaki
H
Division of Pulmonary Medicine, Department of Medicine, Jichi Medical School, Tochigi, Japan. hyamasa@jichi.ac.jp
Sugiyama
Yukihiko
Y
Bando
Masashi
M
Ohno
Shoji
S
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D015897:Comorbidity; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000453:epidemiology; D008168:Lung / Q000000981:diagnostic imaging; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000453:epidemiology*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate